Shares of WeedMD (TSXV:WMD,OTCQX:WDDMF) jumped last week after a dual financing and acquisition announcement on November 29. Now the company says it is looking to move forward on “financially stable footing” in 2020.

The Ontario-based firm shocked investors with the simultaneous release of its results for the third quarter and its plans to acquire Starseed Holdings in an all-stock, arm’s length deal valued at C$78 million. Along with the acquisition, WeedMD also got its hands on a C$25 million equity investment from the Laborers’ Pension Fund of Central and Eastern Canada, Starseed’s largest backer.

In an email statement to the Investing News Network (INN), Keith Merker, CEO of WeedMD, said the firm is currently focused on closing its acquisition of Starseed, set to be completed sometime in December, and on scaling up production.

The influx of cash comes at a notoriously difficult time for cannabis companies, which are struggling to find capital while dealing with volatility across the sector.

“We’re fortunate that the timing has provided us with a relatively risk-free and creative way to inject fresh capital into our business,” Merker told INN, adding that the firm has no other plans to look for capital for now, since it currently boasts a pro forma cash balance of about C$56 million.

Starseed has a partnership with Canada’s largest construction union, the Laborers’ International Union of North America (LiUNA), through which it offers medical cannabis as a fully covered benefit to LiUNA’s more than 100,000 members and retirees.

WeedMD’s initial double-barreled announcement, and the resulting investor confusion, prompted Merker to write an open letter discussing the headwinds that led the company to its deal with Starseed and its newfound financing.

“Capital has become scarce and expensive, and the adult-use market has been slower to ramp and at thinner margins for licensed producers than many originally anticipated,” Merker told investors in the letter. “These market pressures have forced us, like many others, to reevaluate our business.”

The “arm’s length” part of the deal comes from WeedMD’s longstanding relationship with Starseed as a supplier, Merker said, adding that WeedMD has been in talks with Starseed for a more permanent partnership for some time.

As a part of its results for Q3, WeedMD reported an expected outdoor yield of 8 tons of dried cannabis, which came in under its anticipated weight. Merker attributed the lower yield to inexperience with outdoor growing during an earnings call with investors and analysts.

Revenue generation also missed expectations for Q3 at C$6.7 million, down from the nearly C$8 million in Q2 of this year.

Merker chalked up the volatile market reaction to the timing and packaging of the transaction, the quarterly results and the yield that missed the mark. Now, he said, he expects investors will “recalibrate their investment thesis” and consider WeedMD’s augmented position in the recreational cannabis space and new access to the insured benefit channel for medical cannabis.

“Starseed brings a critical part of this business equation that has been difficult for the market to find: consistent, sticky distribution channels with direct access to fully covered and insured patients,” said Merker during the earnings call.

Despite the mixed bag of news from the company, Merker said the transaction is a crucial part of WeedMD’s continued growth.

“The benefit to both WeedMD and Starseed is that we are now providing Starseed’s patients with a consistent supply of medical-grade cannabis. And since we’ll be one company, we don’t envision that much of a transition will be required,” Merker told INN.

Shares of WeedMD took a dip over the trading session on Tuesday (December 10), falling just over 3 percent during the trading day.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less


Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less

The following issues have been halted by IIROC:

Company: Revive Therapeutics Ltd.

Keep reading... Show less